×
About 1,743 results

ALLMedicine™ Chromogranin A Center

Research & Reviews  627 results

Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advan...
https://doi.org/10.1002/cncr.34366
Cancer Hollebecque A, Salvagni S et. al.

Jun 24th, 2022 - CC-90011 is an oral, potent, selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1) that was well tolerated, with encouraging activity in patients who had advanced solid tumors or relapsed/refractory marginal zone lymphoma. The au...

Case 307.
https://doi.org/10.1148/radiol.210250
Radiology Sathiadoss P, Fasih N

Jun 22nd, 2022 - A 45-year-old woman presented to the emergency department with acute worsening of prolonged unexplained nausea, nonbilious vomiting, and mild upper abdominal pain of 4 years duration. Her bowel habits were regular, and there was no history of diar...

Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreati...
https://doi.org/10.4049/jimmunol.2200208
Journal of Immunology (Baltimore, Md. : 1950); Podojil JR, Genardi S et. al.

Jun 21st, 2022 - Type 1 diabetes (T1D) is an autoimmune disease characterized by T and B cell responses to proteins expressed by insulin-producing pancreatic β cells, inflammatory lesions within islets (insulitis), and β cell loss. We previously showed that Ag-spe...

An apparent primitive mass of the mesentery: A case report.
https://doi.org/10.1097/MD.0000000000029464
Medicine Costanzo A, Canziani M et. al.

Jun 18th, 2022 - Neuroendocrine tumours (NETs) are rare tumors. 55% of NETs originate in the gastrointestinal tract and the liver is the most common site of distant metastases. Serum chromogranin A is the most common biomarker for assessing the extent of disease a...

Mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder: case report and li...
https://doi.org/10.1186/s13000-022-01231-6 10.21141/PJP.2019.16 10.1245/s10434-019-07440-6 10.1007/s005340050161 10.1097/00000478-198904000-00004 10.1002/1097-0142(19830515)51:10<1911::AID-CNCR2820511026>3.0.CO;2-L 10.1111/j.1365-2559.1990.tb00772.x 10.1016/S0344-0338(11)80009-9 10.1002/(SICI)1096-9098(199901)70:1<54::AID-JSO10>3.0.CO;2-W 10.1097/00000478-200010000-00014 10.1385/EP:11:4:365 10.1080/136518201753173782 10.1097/00000478-200105000-00005 10.1078/0344-0338-00341 10.1016/j.ijscr.2013.02.013 10.1007/s00535-002-1150-z 10.1111/j.1445-1433.2004.03161.x 10.1272/jnms.73.101 10.1007/s00428-006-0171-z 10.1007/s00595-006-3249-y 10.1111/j.1440-1746.2006.04288.x 10.1111/j.1440-1827.2008.02311.x 10.1136/pgmj.2008.070649 10.1007/s10147-008-0810-2 10.1016/j.prp.2009.10.008 10.1177/030089161109700623 10.1111/j.1440-1827.2011.02709.x 10.1007/s00428-012-1212-4 10.1186/1746-1596-7-163 10.7869/tg.2012.40 10.1007/s12328-012-0311-8 10.1007/s12022-012-9229-4 10.1111/pin.12029 10.3748/wjg.v20.i33.11916 10.1111/pin.12188 10.1186/s12957-015-0533-6 10.1177/1066896915580433 10.1007/s12029-015-9745-9 10.4103/0377-4929.168879 10.4132/jptm.2017.08.20 10.1007/s11605-017-3664-y 10.1186/s12957-019-1598-4 10.1007/s12022-020-09605-6 10.1093/jjco/hyt033 10.3748/wjg.v18.i34.4736
Diagnostic Pathology; Ren X, Jiang H et. al.

Jun 18th, 2022 - Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) of the gallbladder are rare malignancies. Here we presented two cases and reviewed the related literature. Our two patients were postoperatively diagnosed with gallbladder MiNENs, which pa...

see more →

Guidelines  3 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expe...
https://doi.org/10.1093/annonc/mdv041
Annals of Oncology : Official Journal of the European Soc... Caplin ME, Baudin E et. al.

Feb 4th, 2015 - Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. Bibliographical ...

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419007
Pancreas Chen H, Sippel RS et. al.

Jul 29th, 2010 - Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic para...

see more →

Drugs  13 results see all →

Clinicaltrials.gov  39 results

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
https://clinicaltrials.gov/ct2/show/NCT02826928

Jun 7th, 2022 - This study primarily aims at comparing the sensitivity and specificity of overnight 5HIAA value, 24-hour 5HIAA value and plasma 5HIAA value, in patients with small-intestine neuroendocrine tumors. Secondary objectives include the correlation of 5H...

Surgical Intervention and the NETest
https://clinicaltrials.gov/ct2/show/NCT03012789

May 9th, 2022 - Biomarker-based tools that can accurately predict gastroenteropancreatic neuroendocrine tumor (GEP-NET) treatment response and tumor recurrence are currently not available. Circulating biomarkers that are associated with GEP-NETs are limited to me...

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
https://clinicaltrials.gov/ct2/show/NCT00569127

Mar 28th, 2022 - PRIMARY OBJECTIVES: I. To compare central review-based progression-free survival in poor prognosis carcinoid patients treated with either depot octreotide (octreotide acetate) plus bevacizumab, or depot octreotide plus interferon (recombinant inte...

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT01229943

Mar 16th, 2022 - PRIMARY OBJECTIVES: l. To assess the progression-free survival rate of patients with locally advanced or metastatic pancreatic neuroendocrine tumors treated with everolimus alone or everolimus plus bevacizumab. SECONDARY OBJECTIVES: I. To compare ...

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy
https://clinicaltrials.gov/ct2/show/NCT03017794

Jan 28th, 2022 - Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) cells. Accumulated evidences have suggested that the prevalence of ...

see more →

News  15 results

Colchicine Promising for Autoimmune Pancreatitis?
https://www.medpagetoday.com/gastroenterology/pancreaticdiseases/94956

Oct 11th, 2021 - Treatment with the anti-inflammatory drug colchicine resolved recurrent type 2 autoimmune pancreatitis (AIP) in patients who previously received other drugs, a case series in Italy found. Two patients with type 2 AIP experienced clinical improveme...

Surufatinib Improves PFS in Advanced Pancreatic NETs
https://www.onclive.com/view/surufatinib-improves-pfs-in-advanced-pancreatic-nets

Dec 20th, 2020 - The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival (PFS) benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs),...

FDA Approves Copper Cu 64 Dotatate Injection for Somatostatin Receptor–Positive NETs
https://www.onclive.com/view/fda-approves-copper-cu-64-dotatate-injection-for-somatostatin-receptor-positive-nets

Sep 10th, 2020 - The FDA has approved copper Cu 64 dotatate injection (Detectnet) for the localization of somatostatin receptor–positive neuroendocrine tumors (NETs), according to an announcement from RadioMedix Inc. and Curium Pharma.1 The positron emission tomo...

Cystic Scalp Lesion
https://www.mdedge.com/dermatology/article/200643/nonmelanoma-skin-cancer/cystic-scalp-lesion?channel=245
Rosalind Ashton, MD, MSc, Sophia A. Colantonio, MD, MPH et. al.

May 9th, 2019 - The Diagnosis: Merkel Cell Carcinoma An excisional biopsy revealed that the dermis was mostly replaced by a malignant neoplastic infiltrate morphologically resembling small cell carcinoma (Figure 1). The cells had uniform hyperchromatic nuclei wit.

see more →